WO2022149568A1 - ヒトを含めた生物の細胞にある転写産物および、遺伝子導入されたrnaとその複合体精製ツール - Google Patents
ヒトを含めた生物の細胞にある転写産物および、遺伝子導入されたrnaとその複合体精製ツール Download PDFInfo
- Publication number
- WO2022149568A1 WO2022149568A1 PCT/JP2022/000040 JP2022000040W WO2022149568A1 WO 2022149568 A1 WO2022149568 A1 WO 2022149568A1 JP 2022000040 W JP2022000040 W JP 2022000040W WO 2022149568 A1 WO2022149568 A1 WO 2022149568A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rna
- protein
- domain
- crispr
- dcas
- Prior art date
Links
- 230000002103 transcriptional effect Effects 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 150
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 148
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 138
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 38
- 108020005004 Guide RNA Proteins 0.000 claims abstract description 34
- 230000027455 binding Effects 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 22
- 101710163270 Nuclease Proteins 0.000 claims abstract description 16
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 10
- 230000004044 response Effects 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 62
- 239000013598 vector Substances 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 49
- 238000004458 analytical method Methods 0.000 claims description 29
- 230000014509 gene expression Effects 0.000 claims description 26
- 102000040430 polynucleotide Human genes 0.000 claims description 23
- 108091033319 polynucleotide Proteins 0.000 claims description 23
- 239000002157 polynucleotide Substances 0.000 claims description 23
- 108091005804 Peptidases Proteins 0.000 claims description 22
- 239000004365 Protease Substances 0.000 claims description 22
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 22
- 230000037356 lipid metabolism Effects 0.000 claims description 22
- 108020004414 DNA Proteins 0.000 claims description 21
- 150000001413 amino acids Chemical group 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 108020004999 messenger RNA Proteins 0.000 claims description 19
- 241000711573 Coronaviridae Species 0.000 claims description 18
- 230000003834 intracellular effect Effects 0.000 claims description 18
- 108091046869 Telomeric non-coding RNA Proteins 0.000 claims description 17
- 229940124597 therapeutic agent Drugs 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 230000000295 complement effect Effects 0.000 claims description 13
- 230000000069 prophylactic effect Effects 0.000 claims description 9
- 108091027963 non-coding RNA Proteins 0.000 claims description 7
- 102000042567 non-coding RNA Human genes 0.000 claims description 7
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 6
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 6
- 229960005370 atorvastatin Drugs 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 229960000672 rosuvastatin Drugs 0.000 claims description 6
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 5
- 239000013600 plasmid vector Substances 0.000 claims description 5
- 239000007790 solid phase Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims description 3
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims description 3
- 108020005198 Long Noncoding RNA Proteins 0.000 claims description 3
- 230000004570 RNA-binding Effects 0.000 claims description 3
- 108020004417 Untranslated RNA Proteins 0.000 claims description 3
- 102000039634 Untranslated RNA Human genes 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 241000029590 Leptotrichia wadei Species 0.000 claims description 2
- 108010065064 acetaldehyde dehydrogenase (acylating) Proteins 0.000 claims description 2
- 230000008827 biological function Effects 0.000 claims description 2
- 230000009918 complex formation Effects 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 abstract description 3
- 108091035715 XIST (gene) Proteins 0.000 description 39
- 241001678559 COVID-19 virus Species 0.000 description 38
- 230000008685 targeting Effects 0.000 description 22
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 21
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 21
- 108091007416 X-inactive specific transcript Proteins 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 108060001084 Luciferase Proteins 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 108020003589 5' Untranslated Regions Proteins 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 12
- 108091023045 Untranslated Region Proteins 0.000 description 11
- 238000010586 diagram Methods 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 239000005089 Luciferase Substances 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 239000005090 green fluorescent protein Substances 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
- 108010033040 Histones Proteins 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000001114 immunoprecipitation Methods 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 208000002151 Pleural effusion Diseases 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 238000007481 next generation sequencing Methods 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 4
- 108091062183 EsiRNA Proteins 0.000 description 4
- 101150005609 MED20 gene Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 3
- 208000001528 Coronaviridae Infections Diseases 0.000 description 3
- 108010069091 Dystrophin Proteins 0.000 description 3
- 108700009124 Transcription Initiation Site Proteins 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000005026 transcription initiation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- 102100026105 3-ketoacyl-CoA thiolase, mitochondrial Human genes 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000001039 Dystrophin Human genes 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 101000835276 Homo sapiens 3-ketoacyl-CoA thiolase, mitochondrial Proteins 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N alpha-ketodiacetal Natural products O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000010201 enrichment analysis Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108010051779 histone H3 trimethyl Lys4 Proteins 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000002473 ribonucleic acid immunoprecipitation Methods 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- -1 transformants Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
- 101100123845 Aphanizomenon flos-aquae (strain 2012/KM1/D3) hepT gene Proteins 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 238000010196 ChIP-seq analysis Methods 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101001098833 Homo sapiens Proprotein convertase subtilisin/kexin type 6 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 102100038946 Proprotein convertase subtilisin/kexin type 6 Human genes 0.000 description 1
- 102100038950 Proprotein convertase subtilisin/kexin type 7 Human genes 0.000 description 1
- 101710180647 Proprotein convertase subtilisin/kexin type 7 Proteins 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 108700010904 coronavirus proteins Proteins 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000028503 regulation of lipid metabolic process Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010809 targeting technique Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to a CRISPR-dCas / Cas protein derivative or set, a polynucleotide or its complementary strand, a vector, a transformant, a carrier, a method for purifying a target RNA, a method for analyzing an intracellular environment, a prophylactic or therapeutic agent for a novel coronavirus.
- a CRISPR-dCas / Cas protein derivative or set a polynucleotide or its complementary strand, a vector, a transformant, a carrier, a method for purifying a target RNA, a method for analyzing an intracellular environment, a prophylactic or therapeutic agent for a novel coronavirus.
- RNAs in the living body of which about 300 are the subject of research, and about 99% of human RNAs have not been elucidated in function.
- the number of human proteins is about 21,000, of which about 70% is the subject of research.
- RNA is a gene that is transiently expressed in each cell, and it is difficult to recognize antibodies or label with biotin, etc., so a specific base sequence can be obtained under arbitrary conditions. This is because it is difficult to purify the RNA contained in it.
- One object of the present invention is to provide a targeting technique capable of evaluating RNA molecular function.
- Another object of the present invention is to visualize the intracellular behavior of RNA having a specific base sequence.
- an object of the present invention is to provide a prophylactic or therapeutic agent for a new type of coronavirus, or a therapeutic agent for a disease caused by an abnormality in splicing of mRNA.
- the present invention relates to the following CRISPR-dCas / Cas protein derivatives or sets, polynucleotides or complementary strands thereof, vectors, transformants, carriers, methods for purifying target RNA, methods for analyzing intracellular environment, prevention of new coronavirus, or It provides a therapeutic agent and a therapeutic agent for diseases caused by abnormal splicing of mRNA.
- Item 1 CRISPR-dCas / Cas protein derivatives or sets, polynucleotides or complementary strands thereof, vectors, transformants, carriers, methods for purifying target RNA, methods for analyzing intracellular environment, prevention of new coronavirus, or It provides a therapeutic agent and a therapeutic agent for diseases caused by abnormal splicing of mRNA.
- a CRISPR-dCas (dead Cas) protein having a helix region forming a complex with a guide RNA and a target RNA, and having no nuclease activity, or a CRISPR-Cas protein having a nuclease activity
- the helix region The N domain including the N-terminal side and the C domain containing the C-terminal, including the first and second factors that can bind in response to a stimulus, the N domain and the first factor, and the C domain and the second factor are linked, respectively.
- Factors 1 and 2 are bound by a linker containing a protease recognition sequence, or Factors 1 and 2 are bound by a linker containing a self-cleaving peptide, or Factors 1 and 2 are bound.
- Factors are non-covalently linked and become (N-domain)-(first factor)-(linker containing protease recognition sequence)-(second factor)-(C-domain) or (N-domain)-(first).
- the CRISPR-dCas / Cas protein according to Item 1 wherein the N domain contains a part of the amino acid sequence on the N-terminal side of the helix region, and the C domain contains a part of the amino acid sequence on the C-terminal side of the helix region.
- protein derivatives, or CRISPR-dCas / Cas proteins and protein derivative sets Item 3.
- the N domain contains 164 amino acids of a part of the amino acid sequence on the N-terminal side of the helix region of Cas13a (Sequence ID: WP_021746774.1) derived from Leptotrichia wadei, and the C domain is a part of the C-terminal side of the helix region.
- the N domain contains 164 amino acids of a part of the amino acid sequence on the N-terminal side of the helix region of Cas13a (Sequence ID: WP_021746774.1) derived from Leptotrichia wadei
- Item 3. The CRISPR-dCas / Cas protein derivative or CRISPR-dCas / Cas protein according to any one of Items 1 to 3, wherein the first factor contains nMAG or pMAG and the second factor contains pMAG or nMAG. And protein derivative set.
- Item 6. Item 1 or 2 vector containing the 1 or 2 polynucleotide according to Item 5 or a complementary strand thereof.
- Item 7. Item 6. The vector according to Item 6, wherein the vector is an adenovirus vector, an adeno-associated virus vector, or a plasmid vector.
- Item 8 A term in which the vector is two kinds of vectors, one vector has a (N domain)-(first factor) structure, and the other vector has a (second factor)-(C domain) structure.
- Item 6. The vector according to any one of Items 6 to 8, wherein the vector further contains a polynucleotide encoding a guide RNA corresponding to a target RNA.
- Item 10. A transformant transformed by the vector according to any one of Items 6 to 9.
- Item 11. Item 6.
- Item 12. Item 12. The transformant according to Item 11, wherein the transformant is a transformed mammalian cell or a transformed non-human mammal.
- Item 13. Item 6. The CRISPR according to any one of Items 1 to 4, wherein the target RNA is RNA derived from RNA virus, RNA of new coronavirus, RNA derived from synthetic gene, lncRNA, ncRNA of 30 nt or more or preRNA that can be targeted by guide RNA.
- a carrier for purifying target RNA which comprises supporting a CRISPR-dCas (dead Cas) protein that can form a complex with a guide RNA and a target RNA and has no nuclease activity on a solid phase carrier.
- a method for purifying a target RNA comprising eluting a target RNA binding factor selected from the group consisting of, protein, and non-target RNA.
- Item 2. A step of introducing or expressing a plurality of guide RNAs into the transformant according to Item 10, a step of dissolving the transformant to capture the target RNA in the RNA capture particles, and a step of capturing the target RNA bound to the RNA capture particles.
- a method for analyzing an intracellular environment including a step of analysis.
- Item 17. Item 16. The analysis method according to Item 16, wherein the transformant is an iPS cell.
- Item 16. The analysis method according to Item 16 or 17, comprising the step of recovering the expression system of the cell generated by the complex formation of the target RNA, the guide RNA and the photoactivated dCas protein.
- Item 19. A prophylactic or therapeutic agent for a new type of coronavirus containing a lipid metabolism regulator as an active ingredient.
- Item 20. Item 19.
- Item 21. The prophylactic or therapeutic agent for the new coronavirus according to Item 19 or 20, wherein the lipid metabolism regulator is atorvastatin or rosuvastatin.
- Item 22. A therapeutic agent for a disease caused by abnormal splicing of mRNA, rRNA (ribosomal RNA) and lncRNA, which comprises the vector according to any one of Items 6 to 9 as an active ingredient.
- lncRNA long non-coding RNA having a desired base sequence can be easily purified.
- the division of the Cas13 protein into peptides based on the division position according to the present invention can also be applied to Cas13 (Cas13) having ribonuclease activity, and can be used as activated Cas13.
- the divided Cas13 / dCas13 according to the present invention can be applied to known uses of Cas13 / dCas13 other than the above.
- the intracellular target RNA can be purified or captured, and the intracellular environment can be analyzed.
- the intracellular behavior of lncRNA having a desired base sequence can be visualized.
- RNA virus especially new coronavirus infection.
- RNA complex purification method TransRNA Immunoprecipitation (TRIP). Application to modification analysis of RNA function, Precision RNA Sequence Modification (PRSM). Construction of photoactivated Cas13 (PAdCas13) system. Construction of photoactivated Cas13 (PAdCas13) system. Construction of photoactivated Cas13 (PAdCas13) system. Target lncRNAs with high selectivity. RNA visualization example targeting human XIST RNA. Using dCas13 labeled with GFP, the localization of XIST RNA in the cell nucleus could be confirmed in living cells. TRIP method implementation model diagram. Overview of the TRIP method for the untranslated region of SARS-CoV-2.
- TRIP analysis method targeting SARS-CoV-2 1. Performance evaluation of TRIP analysis method targeting SARS-CoV-2 2. Types of RNA to which SARS-CoV-2 derived RNA binds in human cells; Ontology enrichment analysis. Performance evaluation of TRIP analysis method targeting SARS-CoV-2 3. Performance evaluation of TRIP analysis method targeting SARS-CoV-2 4. Data showing that hydrogen bonds of S565 are involved in the binding of atorvastatin and rosuvastatin to HMG-CoA. Performance evaluation of TRIP analysis method targeting SARS-CoV-2 5.
- Left figure A diagram that visualizes whether the binding region of XIST RNA on DNA has regularity around the transcription initiation region of a gene.
- the second column from the left is the test result of the TRIP method for XIST.
- the first column from the left is a negative test that did not use crRNA.
- the third, fourth, and fifth columns from the left are integrated diagrams for histone modification.
- the top is the test result of the TRIP method for XIST. It shows an accumulation pattern similar to that of H3K4me3 in the third stage, suggesting that XIST is a transcription factor.
- TSS transcription start site
- the target defined by the guide RNA was set to long noncoding RNA XIST, and chromatin immunoprecipitation was performed and compared with the existing technique.
- the technique of the present invention was capable of high resolution detection with one or two guide RNAs. The fact that it can be turned ON / OFF immediately and that it can be compared within the RNA molecule is an innovative performance that is difficult to achieve not only with existing technology but also with the original dCas13 protein.
- X-axis distance from the transcription start site (5,000 bp at the right end, -5,000 bp at the left end), Y-axis: average value accumulated in the transcription start region.
- RNA structure analysis data referred to in designing XIRT crRNA, structure prediction diagram, and protein group prediction that binds to the XIST sequence XIST RNA function control verification test using dCas13.
- H3 histone H3
- H3 histone H3
- pENTR1A.dCas13a.GFP pGL3-SARS-CoV-2.ORF1-Promoter. pGL3-SARS-CoV-2.ORF1-Promoter. pGL3-SARS-CoV-2.ORF1-Promoter.
- a virus-derived 5'UTR-mediated translational repression confirmed esiRNA cDNA target sequence.
- Guide RNA targeting introns 1 and 2 of PD-1 pre-mRNA Creation of PD-1 activity-removing lymphocytes using dCas13. Using comprehensive RNA target analysis, we succeeded in creating PD-1 expression-regulated T cells.
- RNA targeted for separation and purification, functional elucidation, disease prevention or treatment in the present invention examples include lncRNA, RNA derived from RNA virus including new coronavirus RNA, and RNA having splicing abnormality.
- Cas5 / dCas5 as a CRISPR-dCas protein having a helix region, capable of forming a complex with a guide RNA and a target RNA, and having no nuclease activity, or a CRISPR-Cas protein having a nuclease activity
- Examples thereof include Cas6 / dCas6, Cas7 / dCas7, Cas9 / dCas9, Cas10 / dCas10, Cas11 / dCas11, and Cas13 / dCas13, with Cas13 / dCas13 being preferred.
- the CRISPR-dCas protein and the CRISPR-Cas protein have a helix region and are cleaved at any of the above-mentioned helix regions, and the N domain on the N-terminal side from the cleavage point and the C domain on the C-terminal side from the cleavage point.
- CRISPR-dCas / Cas protein represented by (C domain) or (N domain)-(first factor)-(linker containing self-cleaving peptide)-(second factor)-(C domain)
- CRISPR-dCas / Cas protein derivative set May be good.
- This set is the "two-part CRISPR-dCas / Cas protein derivative set".
- N domain -(1st factor)-(linker containing protease recognition sequence)-(2nd factor)-(C domain) or
- N domain -(1st factor)-(linker containing self-cleaving peptide)
- One protein represented by-(factor 2)-(C domain) is cleaved with a protease recognition sequence or a self-cleaving peptide, and a polypeptide containing (N domain)-(factor 1) and (second factor). It is a set of polypeptides containing factor)-(C domain).
- the complex becomes a set of a polypeptide containing (N domain)-(factor 1) and a polypeptide containing (factor 2)-(C domain) in which the non-covalent bond is broken in the absence of stimulus.
- Stimuli that promote the binding of the first factor and the second factor include physical stimuli such as light (white light, blue light, etc.), heat (high temperature, low temperature), pH (acidic, neutral, alkaline), pressure, etc. Examples include combinations of ligands and receptors, chemical substances, and the like.
- the stimulus is light
- one of the first factor and the second factor may be nMAG and the other may be pMAG.
- the "non-covalent bond" includes the binding of the first factor and the second factor. For example, when the first factor and the second factor are nMAG and pMAG, the binding of nMAG and pMAG is included in the "non-covalent bond”.
- the protease recognition sequence may be cleaved by an intracellular protease, or a protease that can be cleaved by a protease recognition sequence may be introduced into the cell together with the CRISPR-dCas / Cas protein.
- the length of the linker can be appropriately selected by those skilled in the art, but is preferably a peptide consisting of 3 to 100 amino acids, more preferably 5 to 60 amino acids.
- various protease recognition sequences known in the art can be used (J. Biol. Chem., Vol. 283, No. 30, p20897, 2008).
- the protease recognition sequence is the intracellular protease recognition sequence into which the CRISPR-dCas / Cas protein derivative or protein derivative set is introduced.
- the intracellular protease recognition sequence include amino acid sequences recognized by the intracellular proteases Furin, PC7, and PACE4.
- the linker may be a peptide consisting of a protease recognition sequence or may contain an additional amino acid sequence on the N-terminal side and / or C-terminal side of the protease recognition sequence.
- self-cleaving peptides include literature (Szymczak-Workman, Andrea L et al. “Design and construction of 2A peptide-linked multicistronic vectors.” Cold Spring Harbor protocols vol.
- self-cleaving peptide examples include, but are not limited to, T2A, P2A, E2A, F2A and the like.
- the N domain and the C domain may or may not have a part of the amino acid in the helix region, the amino acid sequence in the helix region may be modified, and a new amino acid sequence is added or inserted. It may have a protease recognition sequence or an amino acid sequence derived from a self-cleaving peptide or linker.
- the present invention includes a CRISPR-dCas / Cas protein derivative, or a polynucleotide encoding a CRISPR-dCas / Cas protein derivative set or a complementary strand thereof.
- Such polynucleotides include: (i) (N domain)-(1st factor)-(linker containing protease recognition sequence)-(2nd factor)-(C domain) or (N domain)-(1st factor)-(self-cleaving peptide) Containing linker)-(second factor)-(C domain) encoding polynucleotide; (ii) A polynucleotide encoding a polypeptide containing (N domain)-(factor 1) and a polynucleotide encoding a polypeptide containing (factor 2)-(C domain) have appropriate spacer nucleotide sequences.
- polynucleotide (iii) Two kinds of polynucleotides consisting of a polynucleotide encoding a polypeptide containing (N domain)-(factor 1) and a polynucleotide encoding a polypeptide containing (factor 2)-(C domain). Set of.
- the vector of the present invention contains any of the above (i) to (iii), is one vector in the case of the above (i) and (ii), and is 2 in the case of the above (iii). It is a set of seed vectors.
- a plasmid vector As the vector, either a plasmid vector or a virus vector may be used.
- the virus vector include an adeno-associated virus vector, an adenovirus vector, a retrovirus vector, and a lentiviral vector.
- the plasmid vector include an entry vector for a Gateway system (pENTR, etc.), a donor vector for gene recombination, a destination vector for parallel transfer, and the like.
- the vector may encode at least one guide RNA in addition to the CRISPR-dCas / Cas protein derivative or the polynucleotide encoding the CRISPR-dCas / Cas protein derivative set or its complementary strand.
- the transformant of the present invention is prepared by transforming a host cell with the vector of the present invention.
- Hosts include mammals such as humans, mice, rats, rabbits, guinea pigs, hamsters, goats, dogs and monkeys.
- the host cell is an ES cell or a fertilized egg of a non-human mammal
- a non-human mammal can be prepared from the transformed cell, and the transformant of the present invention includes a non-human mammal.
- the target RNA purification carrier of the present invention carries a plurality of CRISPR-dCas (dead Cas) proteins that can form a complex with a guide RNA and a target RNA and do not have nuclease activity on a solid phase carrier.
- CRISPR-dCas (deadCas) protein having no nuclease activity include dCas5, dCas6, dCas7, dCas9, dCas10, dCas11, and dCas13, with dCas13 being preferred.
- a solid-phase carrier for supporting the CRISPR-dCas protein known carriers such as silica soil, activated charcoal, alumina, titanium oxide, crosslinked starch particles, cellol-based polymers, chitin and chitosan derivatives can be used.
- RNA purification carrier As a method for immobilizing a CRISPR-dCas protein on a solid phase carrier, known methods such as a physical adsorption method, an ionic bonding method, a comprehensive method, and a covalent bonding method can be used, and among them, the covalent bonding method is used. Excellent long-term stability and desirable.
- a method for co-bonding the dCas protein various methods such as using a compound having an aldehyde group such as formaldehyde, glyoxal, and glutaraldehyde, using a polyfunctional acylating agent, and cross-linking a sulfhydryl group can be used. Available.
- the target RNA purification carrier is preferably used by filling it in a column reactor.
- FIG. 1 illustrates a method for functionally analyzing a target RNA in a cell or in a cytolytic solution using the CRISPR-dCas / Cas protein derivative of the present invention.
- photoactivated dCas13 is used as the CRISPR-dCas protein
- inactivated dCas13 is dCas13 before irradiation with blue light or white light (dark place)
- activated dCas13 is after irradiation with light containing blue light or white light. It is dCas13 of (Mingsho).
- crRNA, inactivated dCas13, and target RNA are present separately, but when activated dCas13 is produced by light irradiation, a complex of crRNA-activated dCas13-target RNA is formed.
- the target RNA may be bound to DNA, non-target RNA, protein, and the like.
- FIG. 1 shows an example in which DNA, RNA or protein is complexed with the target RNA.
- the DNA or RNA is separated from the target RNA and analyzed by real-time PCR (qPCR) next-generation sequencing (NGS), so that the DNA or RNA to which the target RNA binds is bound. Can be identified.
- qPCR real-time PCR
- NGS next-generation sequencing
- the protein to which the target RNA binds can be identified by separating the protein from the target RNA and performing proteome analysis.
- the sequence of target RNA can be determined by analysis in combination with qPCR and NGS.
- the intracellular environment can be analyzed by these analyses.
- FIG. 2 shows the analysis results of the intracellular environment after inducing differentiation of iPS cells.
- the crRNA sequence can be designed based on the crRNA algorithm based on RNA higher-order structure prediction.
- Information on the target RNA can be obtained by binding a large number of crRNAs to the CRISPR-dCas protein on the target RNA purification carrier and sequencing a large number of target RNAs in the sample bound thereto. For example, when a group of lncRNA (long noncoding RNA) expressed at the time of disease can be determined from a sample derived from cells of the disease, or when a group of lncRNA expressed at the time of disease has already been sequenced. In the meantime, effective drug candidate compounds can be screened by monitoring how the expression pattern changes depending on the drug candidate compound. Since many relationships between a certain disease and lncRNA are known, crRNA can be designed with reference to such information.
- a photoactivated dCas protein system (PAdCas system) can be used to observe the expression, distribution, migration, etc. of lncRNA in cells.
- PAdCas system photoactivated dCas protein system
- FIG. 2 shows an example in which the cells of the present invention are applied to PRSM (Precision RNA Sequence Modification).
- FIGS. 3-5 show an example of the PAdCas system of the present invention.
- the PAdCas system contains the N-terminal portion of the CRISPR-dCas protein containing the guide RNA recognition domain (corresponding to ILwaCas13a.N-N MAG in FIGS. 3-5) and the second portion containing the HEPN domain (FIGS. 3-5). It is divided into ILwaCas13a.C-P MAG), and when cells containing these are irradiated with blue light or white light, the current formation of nMAG and pMAG changes and they bind to become an active dCas protein.
- the complex formed by binding the intracellular crRNA and the target RNA can be detected by the labeling of active dCas (for example, a fluorescent protein such as green fluorescent protein).
- active dCas for example, a fluorescent protein such as green fluorescent protein.
- the protein / CRISPR-Cas / dCas protein used in the present invention that can form a complex with a guide RNA and a target RNA and has or does not have RNA nuclease activity can control the RNA splicing mechanism.
- Duchenne muscular dystrophy in the case of a patient in which a stop codon is introduced into the 44th exon, Duchenne muscular dystrophy is treated by introducing a guide RNA for skipping Cas13 and exon 44 of the present invention into cells. be able to.
- RNA splicing abnormalities such as Duchenne muscular dystrophy are shown in Tables 1 to 4 below.
- the present invention further provides a therapeutic agent for a new coronavirus capable of suppressing the growth of the new coronavirus in the body of mammals including humans.
- the research of the present inventor revealed that the protein of the new coronavirus is biosynthesized using the lipid metabolism pathway of mammals, especially humans.
- the present inventor suppresses the biosynthesis of the new coronavirus protein in the lipid metabolism pathway, thereby preventing the virus infection, and further suppresses the growth of the virus even if the virus infection is established, thereby causing the symptoms of the new coronavirus infection.
- a lipid metabolism regulator was tested as a substance that can alleviate the virus and suppress its aggravation, the lipid metabolism regulator should be administered to mammals such as humans, especially humans to whom the lipid metabolism regulator has not been administered.
- lipid metabolism regulators are particularly useful in the prevention of new coronavirus infections due to their low toxicity.
- the dose of the lipid metabolism control substance is about 1 to 150 mg per day for a human adult, and this can be divided and administered once to 4 times a day.
- lipid metabolism regulators include, but are not limited to, mevastatin, atorvastatin, pravastatin, rosuvastatin, fluvastatin and lovastatin.
- the lipid metabolism regulator is preferably one having an HMG-CoA reductase inhibitory action.
- Preferred lipid metabolism regulators include atorvastatin and rosuvastatin.
- PD-1 can be suppressed by applying the present invention to NK cells.
- pleural effusion or peritoneal dissemination can be treated by taking out the pleural effusion or ascites of a patient with pleural effusion or peritoneal dissemination, suppressing PD-1 of NK cells contained in the pleural effusion or ascites, and returning the pleural effusion or ascites to the pleural effusion or ascites.
- an anti-PD-1 antibody and the dCas13 complex of the present invention can be combined.
- PD-1 expression T cells are activated not only from the antibody but also from inside the T cells. Cancer can be treated more effectively by eliminating the disease.
- dCas13 which targets PD-1 pre-mRNA, can be expressed in human lymphocytes to control splicing depending on external stimuli.
- Example 1 RNA complex purification method using Trans RNA Immunoprecipitation (TRIP)
- TRIP Trans RNA Immunoprecipitation
- An RNA target sequence recognition and binding system known as the CRISPR-dCas protein eg, CRISPR-dCas 13, hereinafter abbreviated as "dCas 13"
- dCas 13 a guide RNA
- a complex of dCas proteins without nuclease activity designed to be bifurcated, such as a combination of pMAG and nMag that can be bound by light irradiation recognizes the targeted gene and forms a complex. .
- dCas 13 RNA target sequence recognition and binding system known as the CRISPR-dCas protein
- crRNA guide RNA
- a complex of dCas proteins without nuclease activity designed to be bifurcated such as a combination of pMAG and nMag that can be bound by light irradiation, recognizes the
- inactivated dCas13 corresponds to a state where pMAG and nMAG are separated before light irradiation, and activated dCas13 is a combination of pMAG and nMAG after light irradiation.
- activated dCas13 is a combination of pMAG and nMAG after light irradiation.
- a system using a heat shock protein in which the bound state and the unbound state are reversibly changed depending on the temperature may be used.
- the dCas protein divided into two is in an inactive state, it can be bound and activated by an external stimulus such as light or heat.
- activated means that the CRISPR-dCas protein forms a complex of target RNA and crRNA.
- TRIP technology can be used to extract the complex of targeted RNA, crRNA and dCas13.
- the complex may contain various factors such as other RNAs, DNAs, proteins, etc. that bind to the target RNA. In some cases, it is possible to eliminate specific RNA (ribosomal RNA, etc.) from the cell extract.
- "Turn ON & immunoprecipitation &wash” converts inactivated dCas13 to activated dCas13 by light irradiation (Turn ON), immunoprecipitates the obtained complex (immunoprecipitation), and then cleans and combines.
- RNA target RNA
- proteomics analysis can be performed.
- TRIP technology is applied to the cell extract, but in TRIP technology, the RNA labeling method using Cas13 or dCas13 is applied to both intracellular and cell extracts.
- Example 2 (1) Application to modification analysis of RNA function (Precision RNA Sequence Modification (PRSM))
- PRSM Precision RNA Sequence Modification
- the functional modification of the target RNA can be regulated by switching from Inactive-Cas13 / dCas13 to Active-Cas13 / dCas13 by an external stimulus, and the phenomenon occurs in the cells into which crRNA and Cas13 or dCas13 are introduced at the timing desired by the examiner. Can be observed.
- PRSM Precision RNA Sequence Modification
- FIG. 2 explains the use in Droplet-Sequencing (Drop-Seq).
- Droplet-Sequencing at the timing desired by the tester for a cell group in which arbitrary crRNA (crRNA library in FIG. 2) and Cas13 / dCas13 were introduced and switched to Active-Cas13 / dCas13.
- the function of RNA targeted by crRNA is modified by Active-Cas13 / dCas13.
- the expression level of the transcript can be analyzed as the phenotype for each cell by the next-generation sequence.
- RNA-seq single-cell RNA-seq
- crRNA-seq single-cell RNA-seq
- the expression system of the target RNA and the sequence responsible for the RNA function can be identified.
- Beads in FIG. 2 have a large number of sequences complementary to various RNAs (for example, antisense polynucleotides of a target RNA or a guide RNA) bound to the beads, and the target RNA binds to these beads.
- PA-dCas13 iPS cells
- PA-dCas13 and crRNA may be introduced into iPS cells by a known method capable of introducing proteins and RNA into cells such as liposomes and lipofectamine, and plasmid vectors and viral vectors encoding PA-dCas13 and crRNA may be introduced. It may be introduced into iPS cells to express crRNA and photoactivated dCas13 (PA-dCas13) in the cells.
- light (blue light) stimulation is performed by adding peptides (pMAG and nMAG) having the property of binding to photosensitivity to the C-terminal side of dCas13a.N and the N-terminal side of dCas13a.C, respectively.
- peptides pMAG and nMAG
- Techniques that can be used to reacquire the function of the split Cas13 / dCas13 peptide can be replaced by physical stimuli such as light stimuli, temperature and pressure, as well as chemical stimuli such as ion gradients and drug stimuli.
- Example 3 RNA purification test with crRNA targeting human XIST RNA Binds XIST RNA and XIST from cell extract by immunoprecipitation (TRIP method) via dCas13 using the RNA ChIP method. RNA was purified. It was confirmed that XIST RNA could be extracted with a high degree of purification by the next-generation sequencing method (Fig. 6).
- Gateway® pENTR1A.dCas13a.GFP (Fig. 28A) was prepared as an entry vector corresponding to specific recombination and recombined into a mammalian cell expression vector.
- a lentiviral vector that constitutively expresses crRNA targeting XIST was prepared by inserting the XIST gene sequence into pLKO5.U6.crRNA (gene name) .tRFP.v1 (Fig. 27A).
- FIG. 7 shows an example of RNA visualization targeting human XIST RNA, and the intranuclear localization of XIST RNA could be confirmed in living cells using GFP-labeled photoactivated dCas13 (PAdCas13).
- PAdCas13 GFP-labeled photoactivated dCas13
- FIG. 8 is a TRIP method implementation model diagram.
- FIG. 9 shows an outline of an interaction verification test between RNA derived from SARS-CoV-2 and a human intracellular factor.
- pGL3-SARS-CoV-2.ORF1-Promoter (Fig. 29A) is prepared as a synthetic RNA expression vector fused with virus-derived RNA and a Tag sequence (luciferase sequence) that can be targeted by crRNA.
- a lentiviral vector that constitutively expresses crRNA targeting the luciferase gene was created by inserting the XIST gene sequence into pLKO5.U6.crRNA (gene name) .tRFP.v1.
- crRNA targeting the virus RNA or crRNA targeting the Tag sequence and dCas13 are expressed, converted to Activate-Cas13 / dCas13 at an arbitrary timing, and then the TRIP method is applied. It is used to purify RNA derived from the virus and its complex.
- DNA / RNA we will carry out next-generation sequencing. For proteins, perform proteome analysis.
- Figure 10 shows the outline of the TRIP method for the untranslated region of SARS-CoV-2 that was actually performed. We attempted to elucidate the mechanism by which untranslated sequences derived from SARS-CoV-2 synthesize their own proteins in human cells.
- FIG. 11 shows the structural analysis of the fusion RNA of the Tag sequence (in this figure, the RNA of the Luciferase protein) and the untranslated region of SARS-CoV-2, and the design method of the crRNA sequence for the TRIP method. It can be seen that the untranslated region of SARS-CoV-2 shows a unique structure.
- FIG. 12 shows an outline of RNA immunoprecipitation used in the TRIP method.
- FIG. 12 is a qPCR analysis for confirming the degree of purification recovered by the TRIP method. After introducing only the untranslated region sequence or Tag sequence of the Tag fusion SARS-CoV-2 shown in FIGS. 9 and 10 into HEK293T cells and A549 cells, the TRIP method targeting the Tag sequence was performed, and the recovered RNA was performed. In contrast, the recovery efficiency of the untranslated region sequence of SARS-CoV-2 was compared and examined. The RNA sequence could be recovered only in cells into which Tag-fused SARS-CoV-2 was introduced and immunoprecipitated via Cas13.
- FIG. 13 shows an example of performance evaluation of the TRIP analysis method targeting SARS-CoV-2.
- arrows indicate genes involved in lipid metabolism obtained by immunoprecipitation.
- the RNA of the untranslated region sequence of SARS-CoV-2 has specificity in the RNA sequence that binds in the human cell and significantly binds to the intracellular metabolic mechanism.
- FIG. 14 is another example of performance evaluation of the TRIP analysis method targeting SARS-CoV-2.
- Ontology enrichment analysis revealed that the function of the RNA group recovered in FIG. 13 is the lipid metabolism mechanism.
- FIG. 15 is another example of performance evaluation of the TRIP analysis method targeting SARS-CoV-2.
- ACAA2, HMGcs, FADS1 / 2, and SCD are all factors involved in lipid metabolism and cholesterol metabolism.
- pGL3-5'UTR was expressed in HEK293T and A549 cells, a significant change in gene expression was confirmed as compared with the case where pGL3 was expressed.
- FIG. 16 (b) is an interpretation diagram of the result of FIG. 15 (a).
- the metabolism to the PUFA system was enhanced in A549, and the cholesterol metabolism system was enhanced in HEK293T cells.
- FIG. 16 (c) An attempt was made to suppress HMGcs using an over-the-counter drug, statin.
- the expression of the Luciferase protein enhanced by 5'UTR derived from SARS-CoV-2 was suppressed by statins. At this time, suppression of cell proliferation and transcription of Luciferase RNA could not be confirmed.
- Fig. 16 Suppression of HMGcs and ACAA2 expression by esiRNA was performed, and suppression of Luciferase protein expression enhanced by 5'UTR derived from SARS-CoV-2 was confirmed.
- the range of sequences targeted by esiRNA (MISSION® esiRNA: composed of an inhomogeneous pool of hundreds of siRNAs at 21 bp) is shown in FIG.
- atorvastatin and rosuvastatin have many binding points (S565) when binding to HMG-CoA, which is considered to be one of the reasons why SARS-CoV-2 has a growth inhibitory effect. ..
- FIG. 18 is another example of performance evaluation of a TRIP analysis method targeting SARS-CoV-2, in which the untranslated region sequence of SARS-CoV-2 forms a complex in a host cell containing humans. Show the law. In order for the untranslated region sequence of SARS-CoV-2 (CoV19 in the figure) to bind to human-derived RNA, a certain sequence is required for the factor on the human side, which is the untranslated region of SARS-CoV-2. Predict the presence of proteins that mediate the binding of region sequences to human RNA.
- FIG. 19 is an outline of DNA immunoprecipitation used in the TRIP method, and shows the procedure for extracting and analyzing DNA that binds to XIST RNA.
- FIG. 20 shows a verification test of a light-sensitive switching system. Purification of the XIST-DNA complex via dCas13-crRNA was possible only in light-stimulated cells. The generated genomic DNA was detected by the qPCR method for the known XIST RNA binding region.
- FIG. 21 shows an outline of an example in which it was verified whether the binding region of XIST RNA is related to the histone code in addition to FIG.
- FIG. 22A A diagram visualizing whether the binding region of XIST RNA on DNA has regularity around the transcription initiation region of a gene.
- the second column from the left is the test result of the TRIP method for XIST.
- the first column from the left is a negative test that did not use crRNA.
- the third, fourth, and fifth columns from the left are integrated diagrams for histone modification. Graphs of the accumulation area from the transcription start area in the right and left figures.
- the top is the test result of the TRIP method for XIST. It shows an accumulation pattern similar to that of H3K4me3 in the third stage, suggesting that XIST is a transcription factor.
- FIG. 22B confirms the accumulation in the transcription initiation region from the result of DNA sequencing to the genomic DNA group targeted by XIST extracted from the result of gRNA-dCas13 mediated pulldown (TRIP) targeting XIST which is lncRNA.
- TRIP gRNA-dCas13 mediated pulldown
- the isolated DNA is DNA that interacts with XIST RNA and has been known to be involved in gene transcriptional regulation in contact with histone modifications.
- the results of this test show that the accumulation amount (peak height) exceeds the existing technology (eg, ChIRP, reference: Mol Cell. 2011 Nov 18; 44 (4): 667-78), and the degree of decomposition (peak narrow).
- the result of demonstrating that the XIST target sequence could be extracted in (1) is shown.
- FIG. 23 is RNA structure analysis data referred to in designing XIST crRNA, a structure prediction diagram, and a protein group prediction diagram that binds to the XIST sequence.
- FIG. 24 shows the results of a functional control verification test of XIST RNA by dCas13.
- FIG. 25 shows an application using the photoactivated Cas13 (PAdCas13) system.
- PAdCas13 photoactivated Cas13
- FIG. 24 uses the application shown in FIG. 24, comprehensive RNA function analysis becomes possible.
- PRSM Precision RNA Sequence Modification
- FIG. 26 shows the repair of the (Duchenne) type muscular dystrophy causative factor dystrophin gene mutation at the pre-RNA level.
- Example 4 PD-1 pre-mRNA of PD-1 positive T cells / NK cells (Fig. 31) T cells that have the ability to recognize and eliminate cancer cells misidentify cancer cells as autologous cells by expressing PD-1, but by using dCas13, T cells around the cancer cells It is possible to generate gene-unmodified chimeric antigen receptor T cells that intentionally suppress the expression of PD-1 and specifically attack cancer cells, which will lead to the development of new immunotherapy (Fig. 31).
- the target was the expression of exon 2 of PD-1 pre-mRNA, and by changing the structure of the functional sequence of the splicing control protein that binds to intron 1 and intron 2 of PD-1, the pre of PD-1 was targeted. -The purpose was to control the process from mRNA to mature mRNA. The sequence of the guide RNA targeting each sequence is shown (FIG. 32).
- FIG. 33 Left figure: PA-dCas13 constitutive expression system for human CD8 + T cell line EBT-8, which is a PD-1 expressing cell. After the introduction, a guide RNA targeting the pre-mRNA of PD-1 was introduced. The guide RNA was introduced using a lentiviral vector, and the PD-1 target guide RNAs described above were all introduced simultaneously up to 1-18.
- Chimeric antigen receptor T cells that have been successfully suppressed in expression will be prepared from lymphocytes derived from patient ascites, and their efficacy and safety will be evaluated in an animal model of peritoneal dissemination.
- Example 5 Increased translational activity in Luciferase RNA fused with 5'UTR RNA gene information derived from SARS-CoV-2 was observed (Fig. 34).
- Figure 34 a In the RNA genome of SARS-CoV-2, the region of the 5'UTR gene corresponds to 261 nt located on the 3'side of the ORF1A sequence. The sequence of this 5'UTR region was inserted into the 3'side of the Kozak sequence of the Luciferase RNA sequence of the pGL3-promoter vector.
- Figure 34b Comparative measurement was performed to see if the expression of Luciferase protein increased in HEK293T and A549 cells depending on the amount of pGL3-promoter or pGL3-5'UTR vector introduced. In HEK293T and A549 cells, enhanced expression of Luciferase protein fused with 5'UTR RNA gene information derived from SARS-CoV-2 was observed. This suggests that the 5'UTR derived from SARS-CoV-2 contains a sequence that enhances the translational activity of mRNA fused in human cells.
- FIG. 34c In the test conducted in FIG. 34b, it was confirmed by the qPCR method whether or not the expression level of Luciferase mRNA was changed. No transcriptional enhancement of Luciferase mRNA was confirmed. From the above results, we obtained the results showing that 5'UTR derived from SARS-CoV-2 contains a sequence that enhances the translational activity of mRNA fused in human cells. 5'UTR derived from SARS-CoV-2 is expected to be used for molecular genetics research as a novel IRES-like sequence that enhances the translation efficiency of arbitrary mRNA.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
項1. へリックス領域を有し、ガイドRNA及び標的RNAと複合体を形成でき、かつ、ヌクレアーゼ活性を持たないCRISPR-dCas(dead Cas)タンパク質又はヌクレアーゼ活性を持つCRISPR-Casタンパク質において、前記へリックス領域のN末端側を含むNドメインとC末端を含むCドメイン、刺激に応答して結合可能な第1因子と第2因子を含み、Nドメインと第1因子、Cドメインと第2因子が各々連結され、第1因子と第2因子はプロテアーゼ認識配列を含むリンカーで結合されるか、或いは、第1因子と第2因子は自己切断ペプチド含むリンカーで結合されるか、或いは、第1因子と第2因子が非共有結合されてなり、(Nドメイン)-(第1因子)-(プロテアーゼ認識配列を含むリンカー)-(第2因子)-(Cドメイン)、或いは、(Nドメイン)-(第1因子)-(自己切断ペプチド含むリンカー)-(第2因子)-(Cドメイン)、或いは、(Nドメイン)-(第1因子)-(非共有結合)-(第2因子)-(Cドメイン)の構造を有するCRISPR-dCas/Casタンパク質誘導体、或いは、(Nドメイン)-(第1因子)と(第2因子)-(Cドメイン)の2つの部分を有するCRISPR-dCas/Casタンパク質およびタンパク質誘導体セット。
項2. 前記Nドメインはへリックス領域のN末端側の一部のアミノ酸配列を含み、前記Cドメインはヘリックス領域のC末端側の一部のアミノ酸配列を含む、項1に記載のCRISPR-dCas/Casタンパク質およびタンパク質誘導体、或いは、CRISPR-dCas/Casタンパク質およびタンパク質誘導体セット。
項3. 前記NドメインはLeptotrichia wadei由来のCas13a(Sequence ID:WP_021746774.1)のへリックス領域のN末端側の一部のアミノ酸配列を164アミノ酸含み、前記Cドメインはへリックス領域のC末端側の一部のアミノ酸配列1,003アミノ酸を含む、項1に記載のCRISPR-dCas/Casタンパク質およびタンパク質誘導体、或いは、CRISPR-dCas/Casタンパク質およびタンパク質誘導体セット。
項4. 前記第1因子がnMAG又はpMAGを含み、前記第2因子がpMAG又はnMAGを含む、項1~3のいずれか1項に記載のCRISPR-dCas/Casタンパク質誘導体、或いは、CRISPR-dCas/Casタンパク質およびタンパク質誘導体セット。
項5. 項1~4のいずれかに記載のCRISPR-dCas/Casタンパク質誘導体、或いは、CRISPR-dCas/Casタンパク質誘導体セットをコードするポリヌクレオチド又はその相補鎖。
項6. 項5に記載の1種又は2種のポリヌクレオチド又はその相補鎖を含む1種又は2種のベクター。
項7. 前記ベクターがアデノウイルスベクター、アデノ随伴ウイルスベクター又はプラスミドベクターである項6に記載のベクター。
項8. 前記ベクターが2種のベクターであり、一方のベクターが(Nドメイン)-(第1因子)の構造を有し、他方のベクターが(第2因子)-(Cドメイン)の構造を有する、項7に記載のベクター
項9. 前記ベクターが標的RNAに対応するガイドRNAをコードするポリヌクレオチドをさらに含む、項6~8のいずれか1項に記載のベクター。
項10. 項6~9のいずれか1項に記載のベクターによって形質転換された形質転換体。
項11. 前記標的RNAが生体機能および疾患に関連する一群のlncRNA(long noncoding RNA)および、ncRNA(noncoding RNA)である、項1~4のいずれかに記載のCRISPR-dCas/Casタンパク質およびタンパク質誘導体セット、或いは、CRISPR-dCas/Casタンパク質およびタンパク質誘導体セット、項5に記載のポリヌクレオチド又はその相補鎖、項6~9のいずれか1項に記載のベクター又は項10に記載の形質転換体。
項12. 前記形質転換体が形質転換哺乳動物細胞または形質転換非ヒト哺乳動物である、項11に記載の形質転換体。
項13. 前記標的RNAがRNAウイルス由来のRNA、新型コロナウイルスのRNA、合成遺伝子由来のRNA、lncRNA、ガイドRNAが標的できる30nt以上のncRNA又はプレRNAである、項1~4のいずれかに記載のCRISPR-dCas/Casタンパク質およびタンパク質誘導体、或いは、CRISPR-dCas/Casタンパク質およびタンパク質誘導体セット、項5に記載のポリヌクレオチド又はその相補鎖、項6~9のいずれか1項に記載のベクター又は項10~12のいずれか1項に記載の形質転換体。
項14. ガイドRNA及び標的RNAと複合体を形成でき、かつ、ヌクレアーゼ活性を持たないCRISPR-dCas(dead Cas)タンパク質を固相担体に担持してなる、標的RNA精製用担体。
項15. 項14記載の担体にガイドRNAと標的RNAを作用させて前記担体上に前記標的RNAと前記ガイドRNAと前記CRISPR-dCasタンパク質を含む複合体を形成させる工程、前記複合体から標的RNAおよびゲノムDNA、タンパク質、標的以外のRNAからなる群から選ばれる標的RNA結合因子を溶出させる工程を含む、標的RNAの精製方法。
項16. 項10に記載の形質転換体に複数のガイドRNAを導入もしくは発現させる工程、前記形質転換体を溶解させて標的RNAをRNA捕捉粒子に捕捉させる工程、前記RNA捕捉粒子に結合された標的RNAを解析する工程を含む、細胞内環境の解析方法。
項17. 前記形質転換体がiPS細胞である、項16に記載の解析方法。
項18. 標的RNAとガイドRNAと光活性化されたdCasタンパク質の複合体形成により生じた細胞の表現系を回収する工程を含む、項16又は17に記載の解析方法。
項19. 脂質代謝制御物質を有効成分とする、新型コロナウイルスの予防又は治療剤。
項20. 脂質代謝制御物質がHMG-CoA還元酵素阻害作用またはアセチルCoA還元酵素阻害作用を有する、項19に記載の新型コロナウイルスの予防又は治療剤。
項21. 脂質代謝制御物質がアトルバスタチン又はロスバスタチンである、項19又は20に記載の新型コロナウイルスの予防又は治療剤。
項22. 項6~9のいずれか1項に記載のベクターを有効成分とする、mRNA、rRNA(リボソーマルRNA)およびlncRNAのスプライシング異常に基づく疾患の治療剤。
項23. CRISPR-dCas/Casタンパク質がヌクレアーゼ活性を持つCas13タンパクである、項1に記載のCRISPR-dCas/Casタンパク質およびタンパク質誘導体、或いは、CRISPR-dCas/Casタンパク質およびタンパク質誘導体セット。
(i) (Nドメイン)-(第1因子)-(プロテアーゼ認識配列を含むリンカー)-(第2因子)-(Cドメイン)もしくは(Nドメイン)-(第1因子)-(自己切断ペプチドを含むリンカー)-(第2因子)-(Cドメイン)をコードするポリヌクレオチド;
(ii) (Nドメイン)-(第1因子)を含むポリペプチドをコードするポリヌクレオチドと、(第2因子)-(Cドメイン)を含むポリペプチドをコードするポリヌクレオチドが適当なスペーサーヌクレオチド配列を介して連結された;1つのポリヌクレオチド
(iii) (Nドメイン)-(第1因子)を含むポリペプチドをコードするポリヌクレオチドと、(第2因子)-(Cドメイン)を含むポリペプチドをコードするポリヌクレオチドからなる2種のポリヌクレオチドのセット。
nMAGとpMAGの塩基配列及びアミノ酸配列は文献既知である(Nature Communications volume 6, Article number: 6256 (2015))。
実施例1:Trans RNA Immunoprecipitation (TRIP)を用いたRNA複合体精製手法(図1)
CRISPR-dCasタンパク質(例えば、CRISPR-dCas 13、以下「dCas13」と略すことがある)として知られているRNA標的配列の認識および結合システムは、 標的配列の28個のヌクレオチドを含むガイドRNA(crRNA)と、光照射により結合可能なpMAGとnMagの組合せのような二分割されるようにデザインされたヌクレアーゼ活性を持たないdCasタンパク質の複合体が標的とする遺伝子を認識して複合体を形成する。例えば、図1において、pMAGとnMagでニ分割されたdCas13の場合、inactivated dCas13は、光照射前でpMAGとnMAGが離れた状態に対応し、activated dCas13は、光照射後でpMAGとnMAGが結合した状態に対応する。inactivated dCas13とactivated dCas13は、例えば熱ショックタンパク質を用いた温度により結合状態と非結合状態が可逆的に変化するシステムを用いてもよい。二分割されたdCasタンパク質は不活性(Inactive)状態であるが、光、熱などの外部刺激により結合し再活性化(Activated)させる事ができる。ここで、再活性化(Activated)はCRISPR-dCasタンパク質が標的RNAとcrRNAとの複合体を形成することを意味する。TRIPテクノロジーを使用して、標的とするRNAとcrRNAとdCas13との複合体の抽出が可能となる。前記複合体には標的RNAと結合する、その他のRNA、DNA、タンパク質などの様々な因子が含まれ得る。場合によっては、細胞抽出液からの特定RNA(リボソームRNAなど)の排除なども可能である。図1において、「Turn ON & immunoprecipitation & wash」は、光照射(Turn ON)によりinactivated dCas13をactivated dCas13に変換し、得られた前記複合体を免疫沈降させ(immunoprecipitation)、その後に洗浄して複合体以外の成分を除去することを意味する。その後の抽出(extraction)により、標的RNA(RNA)とそれに結合しているDNA、タンパク質(protein)又は標的以外のRNAを分離し、DNA/RNAは次世代シークエンスにより配列決定し、タンパク質の場合はプロテオーム解析を実施することができる。
(1)RNA機能の修飾解析への応用(Precision RNA Sequence Modification (PRSM))
Cas13もしくはdCas13による標的RNA標識自体が標的としたRNAの機能を修飾する事を利用し、crRNAライブラリーが導入された細胞単位での網羅的なRNAの機能の解析が可能となる。標的RNAの機能修飾は、外部刺激によるInactive-Cas13/dCas13からActive -Cas13/dCas13へとスイッチングで調節可能であり、試験者の望むタイミングでcrRNA及び、Cas13もしくはdCas13が導入された細胞内で現象の観察が可能となる。
Cas13タンパク質の構造解析を行い、HEPN-1及びHEPN-2などの標的RNAの認識及び、crRNAとの結合への影響が少ないと予想されるHelical1領域にて2つのペプチドへの二分割を行った(図3)。分割されたそれぞれのペプチドは、dCas13のN末端ペプチド(Cas13a.N:REC LOBE)、C末端ペプチド(Cas13a.C:NUC LOBE)として二つのペプチドに分けた。
RNA ChIP法を用いて、dCas13を介しての免疫沈降(TRIP法)にて細胞抽出液からXIST RNAとXISTと結合するRNAの精製を行った。次世代シークエンス法にて、XIST RNAが高い精製度で抽出できている事が確認できた(図6)。Gateway(登録商標) 特異的組換えに対応したエントリーベクターとしてpENTR1A.dCas13a.GFP(図28A)を作成し、哺乳動物細胞発現ベクターへの組換えを行った。XISTを標的とするcrRNAを恒常発現するレンチウイルスベクターをpLKO5.U6.crRNA(gene name).tRFP.v1(図27A)にXIST遺伝子配列を挿入する事で作成した。
図23上図のcrRNAの番号に相当したcrRNAを導入した細胞内にてXIST RNAの特定の配列にdCas13を誘導する事で、XIST RNAを介したH3(ヒストンH3)のゲノム上への誘導が阻害されないかと確認した。crRNA1,2,3,5が導入された細胞においてH3のゲノム領域への結合が阻害されており、crRNA1,2,3,5を標的した場合にXISTの機能が阻害される事がわかる。
図24での用途を利用して、網羅的なRNA機能解析が可能となる。(図2のPrecision RNA Sequence Modification (PRSM)法)。用途例として、iPS細胞を用いての分化誘導試験の中で試験者の望むタイミングで標的RNAの配列特異的な機能を阻害する事が可能となる。
がん細胞を認識して排除する能力を持つT細胞はPD-1を発現することで、がん細胞を自己細胞と誤認するが、dCas13を用いることで、がん細胞の周囲にあるT細胞からPD-1 の発現を意図的に抑制してがん細胞を特異的に攻撃する遺伝子非改変キメラ抗原受容体T細胞を作成し、新規免疫療法の開発につなげることができる(図31)。
図33左図:PD-1発現細胞であるヒトCD8+T細胞株EBT-8に対して、PA-dCas13恒常発現系を導入した上で、PD-1のpre-mRNAを標的するガイドRNAの導入を行なった。ガイドRNAの導入はレンチウイルスベクターにて行い、先述のPD-1標的ガイドRNAを1-18まで全て同時に導入した。
図33右図:aの領域にてEBT-8において、PD-1の選択的な発現抑制を確認した。
SARS-CoV-2に由来する5’UTR RNA遺伝子情報を融合したLuciferase RNAでの翻訳活性の亢進を観測(図34)
図34 a : SARS-CoV-2 のRNAゲノムで5’UTR遺伝子の領域はORF1A配列の3’側に存在する261ntに相当する。この5’UTR領域の配列をpGL3-promoter ベクターのLuciferase RNA配列のKozak配列の3’側に融合する形で挿入した。
以上の結果より、SARS-CoV-2に由来する5’UTR にヒトの細胞内で融合するmRNAの翻訳活性を亢進させる配列を含まれることを示す結果を得た。
SARS-CoV-2に由来する5’UTRは、任意のmRNAの翻訳効率を高める新規のIRES様配列として、分子遺伝学研究への活用が期待できる。
Claims (23)
- へリックス領域を有し、ガイドRNA及び標的RNAと複合体を形成でき、かつ、ヌクレアーゼ活性を持たないCRISPR-dCas(dead Cas)タンパク質又はヌクレアーゼ活性を持つCRISPR-Casタンパク質において、前記へリックス領域のN末端側を含むNドメインとC末端を含むCドメイン、刺激に応答して結合可能な第1因子と第2因子を含み、Nドメインと第1因子、Cドメインと第2因子が各々連結され、第1因子と第2因子はプロテアーゼ認識配列を含むリンカーで結合されるか、或いは、第1因子と第2因子は自己切断ペプチド含むリンカーで結合されるか、或いは、第1因子と第2因子が非共有結合されてなり、(Nドメイン)-(第1因子)-(プロテアーゼ認識配列を含むリンカー)-(第2因子)-(Cドメイン)、或いは、(Nドメイン)-(第1因子)-(自己切断ペプチド含むリンカー)-(第2因子)-(Cドメイン)、或いは、(Nドメイン)-(第1因子)-(非共有結合)-(第2因子)-(Cドメイン)の構造を有するCRISPR-dCas/Casタンパク質誘導体、或いは、(Nドメイン)-(第1因子)と(第2因子)-(Cドメイン)の2つの部分を有するCRISPR-dCas/Casタンパク質およびタンパク質誘導体セット。
- 前記Nドメインはへリックス領域のN末端側の一部のアミノ酸配列を含み、前記Cドメインはへリックス領域のC末端側の一部のアミノ酸配列を含む、請求項1に記載のCRISPR-dCas/Casタンパク質およびタンパク質誘導体、或いは、CRISPR-dCas/Casタンパク質およびタンパク質誘導体セット。
- 前記NドメインはLeptotrichia wadei由来のCas13a(Sequence ID:WP_021746774.1)のへリックス領域のN末端側の一部のアミノ酸配列を164アミノ酸含み、前記Cドメインはへリックス領域のC末端側の一部のアミノ酸配列1,003アミノ酸を含む、請求項1に記載のCRISPR-dCas/Casタンパク質およびタンパク質誘導体、或いは、CRISPR-dCas/Casタンパク質およびタンパク質誘導体セット。
- 前記第1因子がnMAG又はpMAGを含み、前記第2因子がpMAG又はnMAGを含む、請求項1~3のいずれか1項に記載のCRISPR-dCas/Casタンパク質誘導体、或いは、CRISPR-dCas/Casタンパク質およびタンパク質誘導体セット。
- 請求項1~4のいずれかに記載のCRISPR-dCas/Casタンパク質誘導体、或いは、CRISPR-dCas/Casタンパク質誘導体セットをコードするポリヌクレオチド又はその相補鎖。
- 請求項5に記載の1種又は2種のポリヌクレオチド又はその相補鎖を含む1種又は2種のベクター。
- 前記ベクターがアデノウイルスベクター、アデノ随伴ウイルスベクター又はプラスミドベクターである請求項6に記載のベクター。
- 前記ベクターが2種のベクターであり、一方のベクターが(Nドメイン)-(第1因子)の構造を有し、他方のベクターが(第2因子)-(Cドメイン)の構造を有する、請求項7に記載のベクター
- 前記ベクターが標的RNAに対応するガイドRNAをコードするポリヌクレオチドをさらに含む、請求項6~8のいずれか1項に記載のベクター。
- 請求項6~9のいずれか1項に記載のベクターによって形質転換された形質転換体。
- 前記標的RNAが生体機能および疾患に関連する一群のlncRNA(long noncoding RNA)および/または、ncRNA(noncoding RNA)である、請求項1~4のいずれかに記載のCRISPR-dCas/Casタンパク質およびタンパク質誘導体セット、或いは、CRISPR-dCas/Casタンパク質およびタンパク質誘導体セット、請求項5に記載のポリヌクレオチド又はその相補鎖、請求項6~9のいずれか1項に記載のベクター又は請求項10に記載の形質転換体。
- 前記形質転換体が形質転換哺乳動物細胞または形質転換非ヒト哺乳動物である、請求項10又は11に記載の形質転換体。
- 前記標的RNAがRNAウイルス由来のRNA、新型コロナウイルスのRNA、合成遺伝子由来のRNA、lncRNA、ガイドRNAが標的できる30nt以上のncRNA又はプレRNAである、請求項1~4のいずれかに記載のCRISPR-dCas/Casタンパク質およびタンパク質誘導体、或いは、CRISPR-dCas/Casタンパク質およびタンパク質誘導体セット、請求項5に記載のポリヌクレオチド又はその相補鎖、請求項6~9のいずれか1項に記載のベクター又は請求項10~12のいずれか1項に記載の形質転換体。
- ガイドRNA及び標的RNAと複合体を形成でき、かつ、ヌクレアーゼ活性を持たないCRISPR-dCas(dead Cas)タンパク質を固相担体に担持してなる、標的RNA精製用担体。
- 請求項14記載の担体にガイドRNAと標的RNAを作用させて前記担体上に前記標的RNAと前記ガイドRNAと前記CRISPR-dCasタンパク質を含む複合体を形成させる工程、前記複合体から標的RNAおよびゲノムDNA、タンパク質、標的以外のRNAからなる群から選ばれる標的RNA結合因子を溶出させる工程を含む、標的RNAの精製方法。
- 請求項10に記載の形質転換体に複数のガイドRNAを導入もしくは発現させる工程、前記形質転換体を溶解させて標的RNAをRNA捕捉粒子に捕捉させる工程、前記RNA捕捉粒子に結合された標的RNAを解析する工程を含む、細胞内環境の解析方法。
- 前記形質転換体がiPS細胞である、請求項16に記載の解析方法。
- 標的RNAとガイドRNAと光活性化されたdCasタンパク質の複合体形成により生じた細胞の表現系を回収する工程を含む、請求項16又は17に記載の解析方法。
- 脂質代謝制御物質を有効成分とする、新型コロナウイルスの予防又は治療剤。
- 脂質代謝制御物質がHMG-CoA還元酵素阻害作用またはアセチルCoA還元酵素阻害作用を有する、請求項19に記載の新型コロナウイルスの予防又は治療剤。
- 脂質代謝制御物質がアトルバスタチン又はロスバスタチンである、請求項19又は20に記載の新型コロナウイルスの予防又は治療剤。
- 請求項6~9のいずれか1項に記載のベクターを有効成分とする、mRNA、rRNA(リボソーマルRNA)およびlncRNAのスプライシング異常に基づく疾患の治療剤。
- CRISPR-dCas/Casタンパク質がヌクレアーゼ活性を持つCas13タンパクである、請求項1に記載のCRISPR-dCas/Casタンパク質およびタンパク質誘導体、或いは、CRISPR-dCas/Casタンパク質およびタンパク質誘導体セット。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022574050A JPWO2022149568A1 (ja) | 2021-01-05 | 2022-01-04 | |
US18/260,452 US20240093168A1 (en) | 2021-01-05 | 2022-01-04 | Transcriptional product in cells of organism including human, transfected rna, and tool for purifying complex thereof |
EP22736736.4A EP4276182A1 (en) | 2021-01-05 | 2022-01-04 | Transcriptional product in cells of organism including human, transfected rna, and tool for purifying complex thereof |
CN202280009159.2A CN116802287A (zh) | 2021-01-05 | 2022-01-04 | 包括人类在内的生物体细胞中的转录产物、转染rna及其纯化复合物的工具 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021000378 | 2021-01-05 | ||
JP2021-000378 | 2021-01-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022149568A1 true WO2022149568A1 (ja) | 2022-07-14 |
WO2022149568A8 WO2022149568A8 (ja) | 2022-09-22 |
Family
ID=82357739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/000040 WO2022149568A1 (ja) | 2021-01-05 | 2022-01-04 | ヒトを含めた生物の細胞にある転写産物および、遺伝子導入されたrnaとその複合体精製ツール |
Country Status (6)
Country | Link |
---|---|
US (1) | US20240093168A1 (ja) |
EP (1) | EP4276182A1 (ja) |
JP (1) | JPWO2022149568A1 (ja) |
CN (1) | CN116802287A (ja) |
TW (1) | TW202241970A (ja) |
WO (1) | WO2022149568A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017139354A1 (en) * | 2016-02-10 | 2017-08-17 | The Regents Of The University Of Michigan | Detection of nucleic acids |
WO2017219027A1 (en) * | 2016-06-17 | 2017-12-21 | The Broad Institute Inc. | Type vi crispr orthologs and systems |
-
2022
- 2022-01-04 EP EP22736736.4A patent/EP4276182A1/en active Pending
- 2022-01-04 WO PCT/JP2022/000040 patent/WO2022149568A1/ja active Application Filing
- 2022-01-04 US US18/260,452 patent/US20240093168A1/en active Pending
- 2022-01-04 CN CN202280009159.2A patent/CN116802287A/zh active Pending
- 2022-01-04 JP JP2022574050A patent/JPWO2022149568A1/ja active Pending
- 2022-01-05 TW TW111100459A patent/TW202241970A/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017139354A1 (en) * | 2016-02-10 | 2017-08-17 | The Regents Of The University Of Michigan | Detection of nucleic acids |
WO2017219027A1 (en) * | 2016-06-17 | 2017-12-21 | The Broad Institute Inc. | Type vi crispr orthologs and systems |
Non-Patent Citations (9)
Title |
---|
ALIZADEH AA ET AL.: "Toward understanding and exploiting tumor heterogeneity", NAT MED, vol. 21, no. 8, August 2015 (2015-08-01), pages 846 - 53 |
DANIELS LORI B.; SITAPATI AMY M.; ZHANG JING; ZOU JINGJING; BUI QUAN M.; REN JUNTING; LONGHURST CHRISTOPHER A.; CRIQUI MICHAEL H.;: "Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients", AMERICAN JOURNAL OF CARDIOLOGY., CAHNERS PUBLISHING CO., NEWTON, MA,, US, vol. 136, 16 September 2020 (2020-09-16), US , pages 149 - 155, XP086340354, ISSN: 0002-9149, DOI: 10.1016/j.amjcard.2020.09.012 * |
DE SPIEGELEER ANTON; BRONSELAER ANTOON; TEO JAMES T.; BYTTEBIER GEERT; DE TRé GUY; BELMANS LUC; DOBSON RICHARD; WYNENDAELE EV: "The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents", JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, ELSEVIER, AMSTERDAM, NL, vol. 21, no. 7, 15 June 2020 (2020-06-15), AMSTERDAM, NL , pages 909, XP086212867, ISSN: 1525-8610, DOI: 10.1016/j.jamda.2020.06.018 * |
J. CLIN. BIOL. CHEM., vol. 283, no. 30, 2008, pages 20897 |
MOL CELL, vol. 44, no. 4, 18 November 2011 (2011-11-18), pages 667 - 78 |
NATURE COMMUNICATIONS, vol. 6, 2015 |
SHAPIRO E ET AL.: "Single-cell sequencing-based technologies will revolutionize whole-organism science", NAT REV GENET, vol. 14, no. 9, 30 July 2013 (2013-07-30), pages 618 - 30, XP055234494, DOI: 10.1038/nrg3542 |
SZYMCZAK-WORKMANANDREA L ET AL.: "Design and construction of 2A peptide-linked multicistronic vectors", COLD SPRING HARBOR PROTOCOLS, vol. 2012, 1 February 2012 (2012-02-01), pages 199 - 204 |
YUTA NIHONGAKI, ET AL.: "Photoactivatable CRISPR-Cas9 for optogenetic genome editing", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 33, no. 7, 15 June 2015 (2015-06-15), New York, pages 755 - 760, XP055321996, ISSN: 1087-0156, DOI: 10.1038/nbt.3245 * |
Also Published As
Publication number | Publication date |
---|---|
WO2022149568A8 (ja) | 2022-09-22 |
TW202241970A (zh) | 2022-11-01 |
JPWO2022149568A1 (ja) | 2022-07-14 |
EP4276182A1 (en) | 2023-11-15 |
CN116802287A (zh) | 2023-09-22 |
US20240093168A1 (en) | 2024-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bourguet et al. | The histone variant H2A. W and linker histone H1 co-regulate heterochromatin accessibility and DNA methylation | |
Gallego-Paez et al. | Alternative splicing: the pledge, the turn, and the prestige: the key role of alternative splicing in human biological systems | |
Peng et al. | Opposing roles of FANCJ and HLTF protect forks and restrain replication during stress | |
Chong et al. | Pooled extracellular receptor-ligand interaction screening using CRISPR activation | |
Hollenbach et al. | Daxx and histone deacetylase II associate with chromatin through an interaction with core histones and the chromatin-associated protein Dek | |
Coady et al. | SMN in spinal muscular atrophy and snRNP biogenesis | |
Wang et al. | Export of microRNAs and microRNA-protective protein by mammalian cells | |
Yarosh et al. | PSF: nuclear busy‐body or nuclear facilitator? | |
Li | The tandem affinity purification technology: an overview | |
Rialdi et al. | The RNA exosome syncs IAV-RNAPII transcription to promote viral ribogenesis and infectivity | |
CA2989830A1 (en) | Crispr enzyme mutations reducing off-target effects | |
JP2016529907A (ja) | 遺伝子発現をサイレンシングする遺伝子制御エレメントを標的とする部位特異的ヌクレアーゼ単一細胞アッセイ | |
JP5721433B2 (ja) | 核酸と直接的または間接的に会合するタンパク質因子の単離 | |
JP2002520074A (ja) | シス作用性核酸エレメントおよび使用法 | |
AU2017238512B2 (en) | Methods for enhancing the efficiency of gene editing | |
Lott et al. | Arginine methylation of DRBD18 differentially impacts its opposing effects on the trypanosome transcriptome | |
San Martin Alonso et al. | Untangling the crosstalk between BRCA1 and R-loops during DNA repair | |
Schalk et al. | DNA damage binding protein2 shapes the DNA Methylation Landscape | |
Boreikaitė et al. | 3′-end processing of eukaryotic mRNA: machinery, regulation, and impact on gene expression | |
Ishov et al. | Coordination of transcription, processing, and export of highly expressed RNAs by distinct biomolecular condensates | |
Kuepper et al. | Constrained peptides mimic a viral suppressor of RNA silencing | |
Taylor et al. | Depletion of Uhrf1 inhibits chromosomal DNA replication in Xenopus egg extracts | |
Schilders et al. | Cell and molecular biology of the exosome: how to make or break an RNA | |
Liu et al. | DNA-initiated epigenetic cascades driven by C9orf72 hexanucleotide repeat | |
WO2022149568A1 (ja) | ヒトを含めた生物の細胞にある転写産物および、遺伝子導入されたrnaとその複合体精製ツール |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22736736 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022574050 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280009159.2 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022736736 Country of ref document: EP Effective date: 20230807 |